1. Featured Article: Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease2. What's Trending: Drug pricing This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 1, 2018, print issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Matthew Barrett about his paper on predictors of psychosis in Parkinson disease. For the "What's Trending" segment, Dr. Ted Burns discusses drug pricing with journalist Ike Swetlitz.DISCLOSURES: Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Barrett has received research support from Axovant Sciences, Inc. (clinical trial site PI), Azevan Pharmaceuticals (clinical trial site PI), Merck Sharp & Dohme Corp. (Clinical trial site PI), Biogen (clinical trial site PI), Virginia Center of Alzheimer´s and Related Diseases Research Award Fund (PI), U.S. Department of Defense Neurotoxin Exposure Treatment Parkinson's Research Career Progress Award (PI), and NIH (clinical trial site PI).Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Mr. Swetlitz is a reporter for StatNews.